Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

Influenza (Healthy Volunteers) Clinical Trial

Official title:
Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older in Taiwan

Status Completed

Clinical Trial Summary

Primary Objective: Immunogenicity: To describe the immune response induced by high-dose quadrivalent influenza vaccine (QIV-HD) and AdimFlu-S (QIS) by hemagglutinin inhibition (HAI) measurement method in all participants. Safety: To describe the safety profile of all participants in each study groups.

Clinical Trial Description

The duration of each participant's participation was approximately 28 days (Day 0 through Day 28 [+ 7 days]). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04537234
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 3
Start date	November 10, 2020
Completion date	February 9, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05568979` - Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23
Completed	`NCT05078060` - Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22
Terminated	`NCT04137887` - Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older	Phase 3
Completed	`NCT05144945` - Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea	Phase 3